The Immune-Modulator Pidotimod Affects the Metabolic Profile of Exhaled Breath Condensate in Bronchiectatic Patients: A Metabolomics Pilot Study
Open Access
- 3 October 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 10, 1115
Abstract
Introduction: Pidotimod, a synthetic dipeptide molecule with biological and immunological activities, is used to reduce the number of exacerbations or pneumonitis in patients with inflammatory diseases. In the present study, we investigated whether Pidotimod modifies the metabolomic pathways measured in the exhaled breath condensate (EBC) of non-cystic fibrosis bronchiectatic patients (NCFB). Materials and Methods: We analyzed 40 adult patients affected by NCFB. They were randomly selected to receive Pidotimod 800 mg b/d for 21 consecutive days (3 weeks) per month for 6 months (20 patients, V1 group) or no drug (20 patients, V0 group), with a 1:1 criterion and then followed as outpatients. Results: EBC samples were collected from all patients at baseline and after 6 months. They were investigated by combined nuclear magnetic resonance (NMR) spectroscopy and multivariate statistical analysis to uncover metabolic differences between EBC from NCFB patients before and after therapy with Pidotimod. Pulmonary function test and pulmonary exacerbations were analyzed at baseline and at the end of Pidotimod therapy. The EBC metabolites were all identified, and through statistical evaluation, we were able to discriminate the two samples’ classes, with acetate, acetoin, lactate, and citrate as statistically significant discriminatory metabolites. The model vas validated by using a blind set of 20 NCFB samples, not included in the primary analysis. No differences were observed in PFT after 6 months. At the end of the study, there was a significant decrease of exacerbation rate in V1 group as compared with V0 group, with a substantial reduction of the number of mild or severe exacerbations (p < 0.001). Discussion: Pidotimod modifies the respiratory metabolic phenotype (“metabotype”) of NCFB patients and reduces the number of exacerbations.Keywords
This publication has 37 references indexed in Scilit:
- Separating Smoking-Related Diseases Using NMR-Based Metabolomics of Exhaled Breath CondensateJournal of Proteome Research, 2013
- Characterization of volatile metabolites taken up by or released from Streptococcus pneumoniae and Haemophilus influenzae by using GC-MSMicrobiology, 2012
- NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosisThorax, 2011
- Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophilsThe Journal of Nutritional Biochemistry, 2011
- Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen‐activated protein Kinase (MAPK) and Phosphatidylinositol‐3‐kinase (PI3K)/AKT pathwaysJournal of Cellular Physiology, 2011
- Metabonomic analysis of exhaled breath condensate in adults by nuclear magnetic resonance spectroscopyEuropean Respiratory Journal, 2008
- Characterisation of the onset and presenting clinical features of adult bronchiectasisRespiratory Medicine, 2006
- A Detoxication Route for Acetaldehyde: Metabolism of Diacetyl, Acetoin, and 2,3-Butanediol in Liver Homogenate and Perfused Liver of RatsThe Journal of Biochemistry, 1996
- Pure absorption gradient enhanced heteronuclear single quantum correlation spectroscopy with improved sensitivityJournal of the American Chemical Society, 1992
- Clean TOCSY for proton spin system identification in macromoleculesJournal of the American Chemical Society, 1988